Mahindra & Mahindra and Ford Motor Company have been called off their much-awaited joint venture in India due to significant changes in the global business environment caused by the pandemic.
The two carmakers have mutually and amicably determined not to complete automotive joint venture plans announced in October 2019.
According to the companies, the fundamental changes in global economic and business conditions over the past 15 months influenced separate decisions to reassess their capital allocation priorities.
Ford said its independent operations in India would continue as is.
Mahindra & Mahindra, which would still produce cars for Ford through contract manufacturing tie-up, said that cancelation of the JV would not impact its product plan, adding that it is accelerating efforts to establish leadership in electric SUVs.
Ford Motor is actively evaluating its businesses worldwide, including in India, to achieve an 8 percent-company adjusted EBIT margin and consistently generate strong adjusted free cash flow.


Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth
US-Iran Conflict Escalates Amid Oil Blockade and Rising Global Tensions
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat
U.S. Stock Futures Edge Higher Ahead of Big Tech Earnings and Fed Decision
Trump-Iran Conflict Escalates as Nuclear Talks Stall and Oil Prices Surge
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth
Trump Urges Iran to Sign Nuclear Deal Amid Ongoing Conflict and Port Blockade
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift
Asian Markets Mixed as Fed Decision, Iran Tensions, and Inflation Data Weigh on Sentiment
Stock Market Update: Fed Holds Rates Steady as Tech Earnings and Geopolitical Tensions Shape Outlook
BOJ Governor Kazuo Ueda Hints at Rate Hike as Inflation Pressures Build
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
Gold Prices Fall as Strong Dollar and Rising Oil Prices Pressure Markets
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings
AI Stocks Rally in Asia as Oil Surge and Hawkish Central Banks Shake Global Markets 



